|

Belinostat Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: Beleodaq, Beleodaq®, PXD 101, PXD-101, PXD101

Pipeline

Phase 1: 2Phase 2: 1Phase 3: 2

Top Sponsors

  • National Cancer Institute (NCI)2
  • University of Utah1
  • Dizal Pharmaceuticals1
  • Corvus Pharmaceuticals, Inc.1

Indications

  • Cancer5
  • Refractory Transformed Non-Hodgkin Lymphoma1
  • Refractory T-Cell Non-Hodgkin Lymphoma1
  • Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type1
  • Recurrent T-Cell Non-Hodgkin Lymphoma1

Other1 trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3

Duarte, California1 trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

City of Hope National Medical Center

Phase 3

Sacramento, California1 trial

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

University of California Davis Comprehensive Cancer Center

Phase 1

Bethesda, Maryland1 trial

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center

Phase 2

Salt Lake City, Utah1 trial

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

Huntsman Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.